Joaquin Duato - 22 Aug 2025 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Signature
/s/ Laura H. McFalls, as attorney-in-fact for Joaquin Duato
Issuer symbol
JNJ
Transactions as of
22 Aug 2025
Net transactions value
-$22,548,655
Form type
4
Filing time
25 Aug 2025, 19:12:16 UTC
Previous filing
19 Mar 2025
Next filing
28 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Duato Joaquin CEO and Chairman of the Board, Director ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK /s/ Laura H. McFalls, as attorney-in-fact for Joaquin Duato 25 Aug 2025 0001673401

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $12,817,691 +125,824 +46% $101.87 401,791 22 Aug 2025 Direct
transaction JNJ Common Stock Sale $22,548,655 -125,824 -31% $179.21 275,967 22 Aug 2025 Direct F1
holding JNJ Common Stock 974 22 Aug 2025 By 401k F2
holding JNJ Common Stock 130,852 22 Aug 2025 By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Employee Stock Options (Right to Buy) Options Exercise $12,817,691 -125,824 -100% $101.87 0 22 Aug 2025 Common Stock 125,824 $101.87 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $178.985 to $179.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2025).
F3 Vested and exercisable one day after the third anniversary of the date of the grant.